ERBB2 and urothelial carcinoma: Following chemotherapy and immune checkpoint immunotherapy, anti-HER2 targeted treatments, such as monoclonal antibodies, small molecule tyrosine kinase inhibitors, and antibody-drug conjugates, have shown significant efficacy in locally advanced or metastatic HER2-positive urothelial carcinoma (27, 28).